Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sulzer Orthopedics Inter-Op

This article was originally published in The Gray Sheet

Executive Summary

Recall of acetabular shells for hip replacement affects roughly 17,750 devices implanted in the U.S. after October 1999, the company announces Dec. 8. Testing of the manufacturing process showed a low percentage of components having a residue of lubricant on the exterior porous surface, which may cause aseptic loosening of the shell, Sulzer explains. "Only a very small number of patients who have received one of these shells may require medical intervention other than post-operative monitoring," the firm says

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel